CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 17, 2017--
Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage
biopharmaceutical company, today announced the promotion of Ted Hibben
to Chief Business Officer. Mr. Hibben has more than 20 years of
experience in business and corporate development, strategy, fundraising
and M&A. Mr. Hibben joined Catabasis in 2015 and previously served as
Senior Vice President, Corporate Development.
“Ted has a successful track record of building value with innovative
product platforms, an ideal fit for our SMART linker platform. The SMART
linker platform has already produced product candidates in multiple
disease areas, creating opportunities for licensing as well as
collaboration,” said Jill C. Milne, Chief Executive Officer of
Catabasis. “Ted has been a significant contributor to the Catabasis
executive team and we look forward to his further leadership in the
Chief Business Officer role and his impact on our corporate strategy.”
Prior to joining Catabasis, Mr. Hibben was Senior Vice President,
Corporate Development at Ensemble Therapeutics, where he formed four
multi-target discovery and development-stage collaborations with
pharmaceutical companies, generating over $1 billion in potential
milestone payments for programs emerging from Ensemble’s macrocycle
library platforms. Previously, Mr. Hibben was Chief Business Officer at
Cequent Pharmaceuticals, where he played an instrumental role in its
2010 merger with MDRNA, Inc. (now Marina Biotech), and was Vice
President, Business Development and Alliance Management at Coley
Pharmaceutical Group, where he sourced and/or managed nine development
alliances and led the sale of Coley to Pfizer in 2008. Ted holds an MBA
from Harvard University and an AB from Dartmouth College.
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted) linker
drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop
additional product candidates. For more information on the Company's
drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005076/en/
Source: Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971